Clinical Trial

Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG Trial

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 2, 2026 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study will compare the outcomes of Vericuguat and placebo in patient with decompensated heart failure . This study will carry out after approval from IERB. Seventy patients fulfilling the inclusion criteria will be enrolled from emergency department. Informed consent will be taken from attendants. A detailed history including name, age, gender, duration of heart failure, history of alcoholism, smoking, diabetes, hypertension, EF at baseline and NYHA class will be noted. Patients will be randomly divided in two groups by using lottery method. Outcomes will be assessed at in terms of hospitalization for heart failure, death from cardiovascular event and side effects.
Trial Details
NCT Number NCT07444398
Lead Sponsor Khawaja Danish Ali
Conditions Decompensated Heart Failure
Enrollment 130 participants
Start Date 2026-01-01
Primary Completion 2026-03-31 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-02